Flupentixol

Flupentixol is an orally active D1/D2 dopamine receptor antagonist and new PI3K inhibitor (PI3Kα IC50=127 nM) . Flupentixol shows anti-proliferative activity to cancer cells and induces apoptosis. Flupentixol can also be used in schizophrenia, anxiolytic and depressive research[1][2][3].

Product Specifications

CAS Number

[2709-56-0]

Product Name Alternative

Flupenthixol

UNSPSC

12352005

Hazard Statement

H315-H319-H320

Target

Apoptosis; Dopamine Receptor; PI3K

Type

Reference compound

Related Pathways

Apoptosis; GPCR/G Protein; Neuronal Signaling; PI3K/Akt/mTOR

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/flupentixol.html

Solubility

10 mM in DMSO

Smiles

OCCN1CCN(CC/C=C2C3=C(SC4=C/2C=CC=C4)C=CC(C(F)(F)F)=C3)CC1

Molecular Formula

C23H25F3N2OS

Molecular Weight

434.52

Precautions

P264-P280-P302+P352-P305+P351+P338-P362

References & Citations

[1]Yonar D, et al. Effect of cis- (Z) -flupentixol on DPPC membranes in the presence and absence of cholesterol. Chem Phys Lipids. 2016 Jun;198:61-71.|[2]Ruhrmann S, et al. Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jun 30;31 (5) :1012-22.|[3]Chao Dong, et al. The antipsychotic agent flupentixol is a new PI3K inhibitor and potential anticancer drug for lung cancer. Int J Biol Sci. 2019 Jun 2;15 (7) :1523-1532.